COMPASS Pathways plc (NASDAQ:CMPS) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of COMPASS Pathways plc (NASDAQ:CMPS) have received an average recommendation of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $30.67.

Several equities research analysts recently weighed in on CMPS shares. Cantor Fitzgerald reissued an “overweight” rating on shares of COMPASS Pathways in a report on Monday, September 9th. Royal Bank of Canada reduced their target price on shares of COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Maxim Group dropped their price target on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Canaccord Genuity Group reduced their price objective on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, August 2nd. Finally, HC Wainwright dropped their target price on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a research report on Friday, November 1st.

COMPASS Pathways Stock Down 0.9 %

CMPS opened at $4.41 on Monday. COMPASS Pathways has a twelve month low of $4.05 and a twelve month high of $12.75. The company’s 50-day moving average price is $5.90 and its two-hundred day moving average price is $6.68. The stock has a market cap of $301.74 million, a price-to-earnings ratio of -2.00 and a beta of 2.29. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.04. During the same period in the prior year, the business earned ($0.67) EPS. As a group, equities analysts expect that COMPASS Pathways will post -2.33 earnings per share for the current year.

Insider Buying and Selling

In other COMPASS Pathways news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $6.05, for a total value of $16,093,000.00. Following the transaction, the insider now directly owns 6,905,774 shares in the company, valued at $41,779,932.70. This represents a 27.81 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.25% of the stock is currently owned by insiders.

Institutional Trading of COMPASS Pathways

A number of large investors have recently modified their holdings of CMPS. Geode Capital Management LLC raised its stake in COMPASS Pathways by 160.3% in the third quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock valued at $266,000 after purchasing an additional 25,970 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of COMPASS Pathways in the 3rd quarter worth $131,000. Point72 Asset Management L.P. purchased a new stake in shares of COMPASS Pathways during the 3rd quarter valued at $371,000. Polar Asset Management Partners Inc. lifted its holdings in shares of COMPASS Pathways by 83.3% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock worth $3,576,000 after acquiring an additional 258,000 shares during the last quarter. Finally, Sio Capital Management LLC grew its position in COMPASS Pathways by 211.7% in the third quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock worth $5,762,000 after acquiring an additional 621,222 shares in the last quarter. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.